Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + VB-111|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 35||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|VB-111||Ofranergene Obadenovec||VB111||Ofranergene Obadenovec (VB-111) is an engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01260506||Phase Ib/II||Bevacizumab + VB-111||Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme||Completed||USA||1|
|NCT04406272||Phase II||Bevacizumab + VB-111||VB-111 in Surgically Accessible Recurrent/Progressive GBM||Active, not recruiting||USA||0|